BridgeMD
New treatment option for Resectable Lung Non-Small Cell Carcinoma
Official title A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
ClinicalTrials.gov ID: NCT06775275
What this study is testing
What is Adebellizumab?
Adebellizumab is an investigational medicine, being studied as a potential treatment for resectable lung non-small cell carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Resectable NSQ NSCLC
- Age 18-65 years
- male or female
- ECOG 0-1
- people have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
You likely can't join if
- SCLC or SQ NSCLC
- previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
- patients who have previously used anti-angiogenic drugs;
- allergic to any component of the study drug or chemotherapy drugs
- patients with any severe and or uncontrolled disease
See the full eligibility criteria
- Resectable NSQ NSCLC
- Age 18-65 years
- male or female
- ECOG 0-1
- people have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
- people must have adequate pulmonary function for the intended pneumonectomy;
- SCLC or SQ NSCLC
- previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
- patients who have previously used anti-angiogenic drugs;
- allergic to any component of the study drug or chemotherapy drugs
- patients with any severe and or uncontrolled disease
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.